University of Pennsylvania
Study of Flurpiridaz F-18 PET/CT as a diagnostic imaging tool to detect abnormal parathyroid glands in patients with primary hyperparathyroidism, prior to multi-parathyroid gland surgical exploration. Patients with known or suspected parathyroid adenomas will be eligible for this study. Comparisons of diagnostic performance using Flurpiridaz F-18 PET/CT versus standard of care dual time point sestamibi SPECT/CT imaging will be tested.
Patients with known or suspected parathyroid adenomas will be eligible for this study. Comparisons of diagnostic performance using Flurpiridaz F-18 PET/CT versus standard of care dual time point sestamibi SPECT/CT imaging will be tested.
Inclusion Criteria: 1. Adult patients, at least 18 years of age 2. History of primary hyperparathyroidism as clinically confirmed by serum laboratory values of elevated calcium levels (\>10.2 mg/dl) and abnormal or inappropriately normal parathyroid hormone concentrations (normal range: 15 to 65 pg/ml). 3. Participants must be informed of the investigational nature of this study and provide written informed consent in accordance with institutional and federal guidelines prior to study-specific procedures. 4. Participants must have had prior SPECT/CT sestamibi parathyroid imaging within 6 mont…
Flurpiridaz is a FDA approved radiopharmaceutical used with PET/CT imaging
Arctuva estimate
Actual pay is set by the research site.
Verify or correct the compensation shown for this listing.